Autolus Therapeutics plc
AUTL
$1.59
$0.117.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.19M | 20.92M | 8.98M | 29.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.19M | 20.92M | 8.98M | 29.00K | -- |
| Cost of Revenue | 56.54M | 25.97M | 44.69M | 138.30M | 40.32M |
| Gross Profit | -35.34M | -5.05M | -35.70M | -138.28M | -40.32M |
| SG&A Expenses | 36.28M | 30.27M | 29.53M | 42.48M | 27.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.82M | 82.14M | 74.22M | 75.89M | 67.65M |
| Operating Income | -71.62M | -61.22M | -65.24M | -75.86M | -67.65M |
| Income Before Tax | -78.59M | -47.52M | -67.94M | -26.14M | -82.07M |
| Income Tax Expenses | 532.00K | 397.00K | 2.23M | 1.46M | 22.00K |
| Earnings from Continuing Operations | -79.12M | -47.92M | -70.16M | -27.61M | -82.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.12M | -47.92M | -70.16M | -27.61M | -82.09M |
| EBIT | -71.62M | -61.22M | -65.24M | -75.86M | -67.65M |
| EBITDA | -69.08M | -58.85M | -62.96M | -73.79M | -65.72M |
| EPS Basic | -0.30 | -0.18 | -0.26 | -0.10 | -0.31 |
| Normalized Basic EPS | -0.18 | -0.11 | -0.16 | -0.06 | -0.19 |
| EPS Diluted | -0.30 | -0.18 | -0.26 | -0.10 | -0.31 |
| Normalized Diluted EPS | -0.18 | -0.11 | -0.16 | -0.06 | -0.19 |
| Average Basic Shares Outstanding | 266.14M | 266.14M | 266.13M | 266.20M | 266.08M |
| Average Diluted Shares Outstanding | 266.14M | 266.14M | 266.13M | 266.20M | 266.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |